Singapore: Gilead Sciences published the results of its operations for the fourth quarter (Q4) and full year 2012. Total revenues for the fourth quarter of 2012 increased 18 percent to $2.59 billion, from $2.20 billion for the fourth quarter of 2011.

Net income for the fourth quarter of 2012 was $762.5 million, or $0.47 per diluted share as compared to $665.1 million, or $0.43 per diluted share for the fourth quarter of 2011. Non-GAAP net income for the fourth quarter of 2012, which excludes acquisition-related, restructuring and stock-based compensation expenses, was $823.4 million, or $0.50 per diluted share as compared to $743.1 million, or $0.49 per diluted share for the fourth quarter of 2011. All earnings per share have been adjusted to reflect the two-for-one stock split that became effective on January 25, 2013.

Full year 2012 total revenues were $9.70 billion, up 16 percent as compared to $8.39 billion for 2011. Net income for 2012 was $2.59 billion, or $1.64 per diluted share, when compared with $2.80 billion, or $1.77 per diluted share for 2011. Non-GAAP net income for 2012, which excludes acquisition-related, restructuring and stock-based compensation expenses, was $3.08 billion, or $1.95 per diluted share, as compared to $3.04 billion or $1.93 per diluted share for 2011.